TY - JOUR
T1 - Preserving the efficacy of antibiotics to tackle antibiotic resistance
AU - Laborda, Pablo
AU - Gil-Gil, Teresa
AU - Martínez, José Luis
AU - Hernando-Amado, Sara
N1 - © 2024 The Author(s). Microbial Biotechnology published by John Wiley & Sons Ltd.
PY - 2024/7
Y1 - 2024/7
N2 - Different international agencies recognize that antibiotic resistance is one of the most severe human health problems that humankind is facing. Traditionally, the introduction of new antibiotics solved this problem but various scientific and economic reasons have led to a shortage of novel antibiotics at the pipeline. This situation makes mandatory the implementation of approaches to preserve the efficacy of current antibiotics. The concept is not novel, but the only action taken for such preservation had been the 'prudent' use of antibiotics, trying to reduce the selection pressure by reducing the amount of antibiotics. However, even if antibiotics are used only when needed, this will be insufficient because resistance is the inescapable outcome of antibiotics' use. A deeper understanding of the alterations in the bacterial physiology upon acquisition of resistance and during infection will help to design improved strategies to treat bacterial infections. In this article, we discuss the interconnection between antibiotic resistance (and antibiotic activity) and bacterial metabolism, particularly in vivo, when bacteria are causing infection. We discuss as well how understanding evolutionary trade-offs, as collateral sensitivity, associated with the acquisition of resistance may help to define evolution-based therapeutic strategies to fight antibiotic resistance and to preserve currently used antibiotics.
AB - Different international agencies recognize that antibiotic resistance is one of the most severe human health problems that humankind is facing. Traditionally, the introduction of new antibiotics solved this problem but various scientific and economic reasons have led to a shortage of novel antibiotics at the pipeline. This situation makes mandatory the implementation of approaches to preserve the efficacy of current antibiotics. The concept is not novel, but the only action taken for such preservation had been the 'prudent' use of antibiotics, trying to reduce the selection pressure by reducing the amount of antibiotics. However, even if antibiotics are used only when needed, this will be insufficient because resistance is the inescapable outcome of antibiotics' use. A deeper understanding of the alterations in the bacterial physiology upon acquisition of resistance and during infection will help to design improved strategies to treat bacterial infections. In this article, we discuss the interconnection between antibiotic resistance (and antibiotic activity) and bacterial metabolism, particularly in vivo, when bacteria are causing infection. We discuss as well how understanding evolutionary trade-offs, as collateral sensitivity, associated with the acquisition of resistance may help to define evolution-based therapeutic strategies to fight antibiotic resistance and to preserve currently used antibiotics.
KW - Anti-Bacterial Agents/pharmacology
KW - Bacteria/drug effects
KW - Bacterial Infections/drug therapy
KW - Humans
KW - Drug Resistance, Bacterial
KW - Animals
UR - http://www.scopus.com/inward/record.url?scp=85198752271&partnerID=8YFLogxK
U2 - 10.1111/1751-7915.14528
DO - 10.1111/1751-7915.14528
M3 - Review
C2 - 39016996
SN - 1751-7915
VL - 17
SP - e14528
JO - Microbial biotechnology
JF - Microbial biotechnology
IS - 7
M1 - e14528
ER -